Treatment with AD-MSC-derived EXOs downregulated inflammatory mediators such as IL-6, CCL-2 and CCL-5 and these anti-inflammatory effects may be mediated by the transfer of miRNAs [107]. This evidence concerns the gene CCL2 and Alzheimer disease.